Promising biomarkers for predicting, monitoring and measuring treatment response

Imaging, blood and digital biomarkers for mental disorders can be used to predict, monitor and measure treatment response. They include glutamate-related biomarkers demonstrated by magnetic resonance spectroscopy, serum brain-derived neurotrophic factor and many new digital biomarkers obtained from smartphones and sensors, explained Professor Gregor Hasler, University of Fribourg, Switzerland at WCP 2021.

Mental disorders are generally characterized by heterogeneous phenotypes but there is a lack of evidence for biologic markers,1 said Professor Gregor Hasler, University of Fribourg, Switzerland. The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnoses2 therefore lack biological validity.

Biomarkers need to have the power to predict treatment response


Characteristics of promising biomarkers

A variety of promising biomarkers have been identified by magnetic resonance imaging (MRI), in the blood and from smartphone and sensor digital data, explained Professor Hasler, and need to

  • be associated with a DSM disease
  • related to the pathogenetic processes
  • have the power to predict treatment response and enable translational research


Glutamate-related biomarkers

Prefrontal glutamine is increased in the early phases of mood and anxiety disorders

Professor Hasler described his own research using a magnetic resonance spectroscopy technique to compare glutamate-related biomarkers in unmedicated adults with major depressive disorder (MDD) and controls.3

It demonstrated abnormal reductions in glutamate/glutamine and gamma-aminobutyric acid (GABA) in dorsomedial/dorsal anterolateral prefrontal brain regions compatible with findings from postmortem histopathologic studies.3,4

Prefrontal glutamine is increased in the early phases of mood and anxiety disorders,5 said Professor Hasler, and further understanding of glutamate–glutamine dysfunction in stress-related disorders may lead to new therapeutic strategies.

High levels of extracellular glutamate damage neural dendrites and spines

In terms of the pathogenetic process, Professor Hasler described research showing that prolonged MDD alters prefrontal glutamate release and reduces glutamate uptake. The resulting high levels of extracellular glutamate damage neural dendrites and lead to decreased spine density and synaptic strength.6


Blood biomarkers

Serum brain-derived neurotrophic factor increases in patients who respond to antidepressants

Neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), and stress-related, inflammatory and epigenetic biomarkers can all be measured in the blood, said Professor Hasler. He highlighted a 2020 systematic review and meta-analysis demonstrating that serum BDNF levels

  • are decreased in patients with MDD
  • increase in patients who respond to antidepressants7


Digital biomarkers

Digital biomarkers are showing promise as biomarkers of mental illness

Digital biomarkers obtained from smartphones and sensors, for instance phone usage, activity and voice characteristics may be associated with specific psychiatric behaviors,8,9 said Professor Hasler. They are likely to play a more prominent role as biomarkers of mental illness in the future.

  1. Hasler G, et al. Neuropsychopharmacology 2004;29:1765–81.
  2. Available at Accessed 30 Mar 21.
  3. Hasler G, et al. Arch Gen Psychiatry 2007;64:193–200.
  4. Rajkowska G, et al. Biol Psychiatry 1999;45:1085–98.
  5. Hasler G, et al. Transl Psychiatry 2019;9:170.
  6. Abdallah CG, et al. Annu Rev Med 2015;66:509–23.
  7. Shi Y, et al. Eur Neuropsychopharmacol 2020;41:40–51.
  8. Spinazze P, et al. BMJ Open 2019;9:e032255.
  9. Low DM, et al. Laryngoscope Invest Otolaryngol 2020;5:96–116.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country